Core Viewpoint - AlphaTON Capital Corp and its subsidiary Cyncado Therapeutics are initiating a clinical trial in Australia for TT-4, a selective A2B receptor antagonist, aimed at treating mesothelioma, with an enrollment of approximately 50 patients [1][9]. Group 1: Clinical Trial Details - The trial is sponsored by the Asbestos and Dust Diseases Research Institute (ADDRI) and will evaluate TT-4's effectiveness in mesothelioma, addressing the urgent need for second-line therapies [1][9]. - The trial will run alongside Cyncado's U.S. activities, pending a definitive agreement and necessary approvals [1][9]. - A/Prof Steven Kao and Dr. Melvin Chin will lead the trial, both of whom have extensive experience in mesothelioma research [4][5]. Group 2: Industry Context - Mesothelioma is an aggressive cancer linked to asbestos exposure, with poor prognosis and no established second-line treatment, highlighting the importance of clinical trials in this area [6]. - Australia has one of the highest per-capita burdens of mesothelioma, making it a critical location for such research [6][3]. - ADDRI aims to contribute high-quality data to inform care for mesothelioma patients both in Australia and internationally [3][7]. Group 3: Company Background - Cyncado Therapeutics is focused on developing small molecule adenosine receptor antagonists to overcome immune suppression in oncology, with TT-4 being their lead program [13]. - The company is advancing toward first-patient dosing for TT-4 in Q1 2026, indicating a commitment to rapid development in this therapeutic area [13].